Zev A Wainberg - JoVE Visualize

Showing results (31-40 of 131) with videos related to

Pageof 14

Sort By:

CPT: Pharmacometrics & Systems Pharmacology|November 9, 2021

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancerKarl Brendel, Tanios Bekaii-Saab, Patrick M Boland, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010

Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivoZev A Wainberg, Adrian Anghel, Amrita J Desai, et al.

Annals of Surgical Oncology|September 6, 2014

Value of primary tumor gene signatures in colon cancer when national quality standards are adhered to: preliminary results of an international prospective multicenter trialAnton J Bilchik, Zev A Wainberg, Aviram Nissan, et al.

Cancer Discovery|April 29, 2021

Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor TherapyMario E Lacouture, Zev A Wainberg, Anisha B Patel, et al.

Investigational New Drugs|January 25, 2014

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsMargaret von Mehren, Carolyn D Britten, Peter Pieslor, et al.

BMC Cancer|July 10, 2020

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimensZev A Wainberg, Kynan Feeney, Myung Ah Lee, et al.

Journal of Gastric Cancer|May 2, 2023

Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW StudyTakatsugu Ogata, Yukiya Narita, Zev A Wainberg, et al.

European Journal of Cancer (Oxford, England : 1990)|May 6, 2021

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II studyZev A Wainberg, Tanios Bekaii-Saab, Patrick M Boland, et al.

Annals of Surgical Oncology|August 15, 2013

Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging systemMatthew M Rochefort, Jacob S Ankeny, Brian E Kadera, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021

18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal AdenocarcinomaMatthias R Benz, Wesley R Armstrong, Francesco Ceci, et al.

Pageof 14

Showing results (31-40 of 131) with videos related to

Sort By:

Pageof 14

CPT: Pharmacometrics & Systems Pharmacology|November 9, 2021

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancerKarl Brendel, Tanios Bekaii-Saab, Patrick M Boland, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010

Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivoZev A Wainberg, Adrian Anghel, Amrita J Desai, et al.

Annals of Surgical Oncology|September 6, 2014

Value of primary tumor gene signatures in colon cancer when national quality standards are adhered to: preliminary results of an international prospective multicenter trialAnton J Bilchik, Zev A Wainberg, Aviram Nissan, et al.

Cancer Discovery|April 29, 2021

Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor TherapyMario E Lacouture, Zev A Wainberg, Anisha B Patel, et al.

Investigational New Drugs|January 25, 2014

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsMargaret von Mehren, Carolyn D Britten, Peter Pieslor, et al.

BMC Cancer|July 10, 2020

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimensZev A Wainberg, Kynan Feeney, Myung Ah Lee, et al.

Journal of Gastric Cancer|May 2, 2023

Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW StudyTakatsugu Ogata, Yukiya Narita, Zev A Wainberg, et al.

European Journal of Cancer (Oxford, England : 1990)|May 6, 2021

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II studyZev A Wainberg, Tanios Bekaii-Saab, Patrick M Boland, et al.

Annals of Surgical Oncology|August 15, 2013

Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging systemMatthew M Rochefort, Jacob S Ankeny, Brian E Kadera, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021

18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal AdenocarcinomaMatthias R Benz, Wesley R Armstrong, Francesco Ceci, et al.

Pageof 14